Pomerantz Law Firm Probes Potential Securities Fraud Involving Corcept Therapeutics Investors

Investor Alert: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Corcept Therapeutics Incorporated

Background

On January 8, 2026, Pomerantz LLP announced their investigation into claims from investors of Corcept Therapeutics Incorporated, known for their focus on drug development and innovative treatments. The law firm is looking into allegations that Corcept, along with certain officers and directors, may have engaged in securities fraud or other unlawful business practices, raising concerns for those who invested in the company.

This investigation was sparked following the release of a critical press statement from Corcept on December 31, 2025. In this statement, the company informed investors that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for their product, relacorilant, which was being evaluated as a treatment for hypertension caused by hypercortisolism. The FDA acknowledged that while Corcept's pivotal GRACE trial met its primary endpoint, they could not conclude a favorable benefit-risk assessment without additional evidence of effectiveness.

Impact on Investors

The news had a significant impact on Corcept's stock, which tumbled by $35.40 per share, a drop of over 50%, closing at $34.80 by the end of that trading day. This sharp price decline prompted immediate concerns among investors, leading to the current investigation by Pomerantz LLP.

According to Pomerantz, investors who faced losses are encouraged to reach out and potentially join a class action that aims to address their grievances. This legal effort is a part of Pomerantz’s long-standing commitment to fighting against corporate misconduct and protecting the rights of investors. Found in major cities such as New York, Chicago, and Los Angeles, Pomerantz is recognized as a preeminent firm in securities class litigation and has a history of securing substantial settlements for clients in similar situations.

What’s Next?

For those affected, now is a crucial time to consider their options. Contact details for Danielle Peyton at Pomerantz are provided for interested investors to get in touch and learn more about the potential legal actions being organized. The law firm encourages investors to proactively seek support to ensure their rights are safeguarded amidst these troubling developments.

On the other hand, Corcept will need to navigate these challenges carefully, addressing both investor concerns and regulatory scrutiny while working to provide the requested evidence to the FDA. The next steps concerning relacorilant will be closely monitored as the company works on additional data to support their application.

In conclusion, this incident highlights the importance of investor vigilance and the potential ramifications of non-compliance with securities laws. Stakeholders are urged to stay informed and consider legal options available to them as this situation develops. Pomerantz remains committed to holding corporations accountable and ensuring that justice is served for those who have been wronged.